Diabetes: a driver for heart failure: Figure 1
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Diabetes and heart failure (HF) often co-exist, and since the number of people with either diabetes or HF is increasing worldwide, the number of diabetic HF patients is expected to grow exponentially. Patients with diabetes and HF have a poorer clinical outcome compared to diabetic patients without HF. Also, HF patients with diabetes have different characteristics compared to HF patients without diabetes. This observation suggests that diabetes might contribute to the onset and progression of HF. Several other findings support the concept that diabetes is a driver for HF. Diabetes might increase the risk of developing HF through the increased risk of atherosclerotic disease. In addition, diabetes directly influences function and structure of the heart—for example, through altered insulin signalling and mitochondrial dysfunction, increased (deposition of) advanced glycation end products (AGEs), oxidative stress, and lipid accumulation. Several treatment guidelines exist for diabetes and HF, but the specific treatment suggestions for diabetics with HF are sparse. Moreover, some treatment options for diabetes are not recommended for those with concomitant HF. This article provides an overview of the current knowledge and understanding regarding the epidemiology, pathophysiology, and treatment of patients with HF and diabetes. ### Prevalence of HF in patients with diabetes In the general population the prevalence of patients with both HF and diabetes is estimated at 0.5% in men and 0.4% in women.1 In patients with diabetes the prevalence of HF is between 9–22%, which is much higher compared to the general population. In a hospital discharge database of the Kaiser Permanente Northwest Division the prevalence of HF was 11.8% in patients with diabetes compared to 4.5% in patients without diabetes (n=1566).w1 The prevalence is highest in women aged 70 years and older.w2 The prevalence of asymptomatic diastolic dysfunction in patients with diabetes is probably higher, and estimated to be between 52–60%.w3 w4 Not all …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · cited 17×
“In a subgroup of the SAVE trial (n¼496), those patients with diabetes and an ejection fraction <40% treated with insulin had a higher risk for cardiovascular mortality and HF hospitalisation.w53 Similar findings were observed in CHARM, where the use of insulin was associated with mortality or hospital admission for HF…”
BackgroundMethodResultInfluentialCardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300 · cited 1×
“In a meta-analysis, rosiglitazone was the only oral hypoglycaemic agent associated with an increased risk of cardiovascular morbidity or mortality, albeit not statistically significant (OR 1.68).”
BackgroundInfluentialTorp-Pedersen, C., Metra, M., Charlesworth, A., Spark, P., Lukas, M. A., Poole-Wilson, P. A., Swedberg, K., Cleland, J. G. F., Di Lenarda, A., Remme, W. J., et al. (2007) · Heart · doi:10.1136/hrt.2006.092379 · Cited by 171
van Melle, J. P., Bot, M., de Jonge, P., de Boer, R. A., van Veldhuisen, D. J., & Whooley, M. A. (2010) · Diabetes Care · doi:10.2337/dc10-0286 · Cited by 159 · cited 1×
“In a recent study in 839 patients with coronary artery disease it was shown that diabetes was a risk factor for HF independent of baseline functional assessment of ischaemia and myocardial infarction.”
Backgroundde Boer, R. A., Doehner, W., van der Horst, I. C. C., Anker, S. D., Babalis, D., Roughton, M., Coats, A. J., Flather, M. D., & van Veldhuisen, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.02.018 · Cited by 39
Cited by
van Deursen, V. M., Urso, R., Laroche, C., Damman, K., Dahlström, U., Tavazzi, L., Maggioni, A. P., & Voors, A. A. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.30 · Cited by 468
Self-citationHeart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Toh, S., Hampp, C., Reichman, M. E., Graham, D. J., Balakrishnan, S., Pucino, F., Hamilton, J., Lendle, S., Iyer, A., Rucker, M., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2568 · Cited by 91
Metadata
- Authors
- Voors, A. A., & van der Horst, I. C. C.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2011-04-07
- Volume
- 97
- Issue
- 9
- Pages
- 774-780
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2110460924
- Cited by
- 40
- References
- 6
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes: a driver for heart failure: Figure 1. https://app.cochat.ai/papers/10.1136/hrt.2009.183624
- The paper
- Voors, A. A., & van der Horst, I. C. C. (2011). Diabetes: a driver for heart failure: Figure 1. Heart. https://doi.org/10.1136/hrt.2009.183624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.